More information on this family may be found on the IUPHAR-DB family and introduction pages.
The GABAA receptor is a ligand-gated ion channel of the Cys-loop family that includes the nicotinic acetylcholine, 5-HT3 and strychnine-sensitive glycine receptors. GABAA receptor-mediated inhibition within the CNS occurs by fast synaptic transmission, sustained tonic inhibition and temporally intermediate events that have been termed ‘GABAA, slow’ [9]. GABAA receptors exist as pentamers of 4TM subunits that form an intrinsic anion selective channel. Sequences of six α, three β, three γ, one δ, three ρ, one ε, one π and one θ GABAA receptor subunits (gene family ID ENSF00000000053) have been reported in mammals [25,35-36,41,51]. The π-subunit is restricted to reproductive tissue. Alternatively spliced versions of many subunits exist (e.g. α4- and α6- (both not functional) α5-, β2-, β3- and γ2), along with RNA editing of the α3 subunit [12]. The three ρ-subunits, (ρ1-3) function as either homo- or hetero-oligomeric assemblies [10,53]. Receptors formed from ρ-subunits, because of their distinctive pharmacology that includes insensitivity to bicuculline, benzodiazepines and barbiturates, have sometimes been termed GABAC receptors [53], but they are classified as GABAA receptors by NC-IUPHAR on the basis of structural and functional criteria [3,35-36].
Many GABAA receptor subtypes contain α-, β- and γ-subunits with the likely stoichiometry 2α.2β.1γ [25,35]. It is thought that the majority of GABAA receptors harbour a single type of α- and β -subunit variant. The α1β2γ2 hetero-oligomer constitutes the largest population of GABAA receptors in the CNS, followed by the α2β3γ2 and α3β3γ2 isoforms. Receptors that incorporate the α4- α5-or α6-subunit, or the β1-, γ1-, γ3-, δ-, ε- and θ-subunits, are less numerous, but they may nonetheless serve important functions. For example, extrasynaptically located receptors that contain α6- and δ-subunits in cerebellar granule cells, or an α4- and δ-subunit in dentate gyrus granule cells and thalamic neurones, mediate a tonic current that is important for neuronal excitability in response to ambient concentrations of GABA [4,13,31,39]. GABA binding occurs at the β+/α- subunit interface and the homologous γ+/α- subunits interface creates the benzodiazepine site. A second site for benzodiazepine binding has recently been postulated to occur at the α+/β- interface ([37]; reviewed by [42]). The particular α-and γ-subunit isoforms exhibit marked effects on recognition and/or efficacy at the benzodiazepine site. Thus, receptors incorporating either α4- or α6-subunits are not recognised by ‘classical’ benzodiazepines, such as flunitrazepam (but see [52]). The trafficking, cell surface expression, internalisation and function of GABAA receptors and their subunits are discussed in detail in several recent reviews [11,20,30,48] but one point worthy of note is that receptors incorporating the γ2 subunit (except when associated with α5) cluster at the postsynaptic membrane (but may distribute dynamically between synaptic and extrasynaptic locations), whereas as those incorporating the d subunit appear to be exclusively extrasynaptic.
NC-IUPHAR [3,35] class GABAA receptors according to their subunit structure, pharmacology and receptor function. Currently, eleven native GABAA receptors are classed as conclusively identified (i.e., α1β2γ2, α1βγ2, α3βγ2, α4βγ2, α4β2δ, α4β3δ, α5βγ2, α6βγ2, α6β2δ, α6β3δ and ρ) with further receptor isoforms occurring with high probability, or only tentatively [35-36]. It is beyond the scope of this Guide to discuss the pharmacology of individual GABAA receptor isoforms in detail; such information can be gleaned in the reviews [3,16,21,25,27,32,35-36,41] and [1-2]. Agents that discriminate between α-subunit isoforms are noted in the table and additional agents that demonstrate selectivity between receptor isoforms, for example via β-subunit selectivity, are indicated in the text below. The distinctive agonist and antagonist pharmacology of ρ receptors is summarised in the table and additional aspects are reviewed in [10,22,33,53].
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Atack, JR. (2008) GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. CNS Neurosci Ther, 14 (1): 25-35. [PMID:18482097]
Atack, JR. (2010) GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci, 2: 331-60. [PMID:21309116]
Barnard, EA; Skolnick, P; Olsen, RW; Mohler, H; Sieghart, W; Biggio, G; Braestrup, C; Bateson, AN; Langer, SZ. (1998) International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev., 50 (2): 291-313. [PMID:9647870]
Belelli, D; Harrison, NL; Maguire, J; Macdonald, RL; Walker, MC; Cope, DW. (2009) Extrasynaptic GABAA receptors: form, pharmacology, and function. J. Neurosci., 29 (41): 12757-63. [PMID:19828786]
Belelli, D; Peden, DR; Rosahl, TW; Wafford, KA; Lambert, JJ. (2005) Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics. J. Neurosci., 25 (50): 11513-20. [PMID:16354909]
Bonin, RP; Orser, BA. (2008) GABA(A) receptor subtypes underlying general anesthesia. Pharmacol. Biochem. Behav., 90 (1): 105-12. [PMID:18201756]
Bowery, NG; Smart, TG. (2006) GABA and glycine as neurotransmitters: a brief history. Br. J. Pharmacol., 147 Suppl 1: S109-19. [PMID:16402094]
Capogna, M; Pearce, RA. (2011) GABA A,slow: causes and consequences. Trends Neurosci., 34 (2): 101-12. [PMID:21145601]
Chebib, M. (2004) GABAC receptor ion channels. Clin. Exp. Pharmacol. Physiol., 31 (11): 800-4. [PMID:15566397]
Chen, ZW; Olsen, RW. (2007) GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J. Neurochem., 100 (2): 279-94. [PMID:17083446]
D'Hulst, C; Atack, JR; Kooy, RF. (2009) The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov. Today, 14 (17-18): 866-75. [PMID:19576998]
Daniel, C; Ohman, M. (2009) RNA editing and its impact on GABAA receptor function. Biochem. Soc. Trans., 37 (Pt 6): 1399-403. [PMID:19909284]
Farrant, M; Kaila, K. (2007) The cellular, molecular and ionic basis of GABA(A) receptor signalling. Prog. Brain Res., 160: 59-87. [PMID:17499109]
Farrant, M; Nusser, Z. (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci., 6 (3): 215-29. [PMID:15738957]
Frølund, B; Ebert, B; Kristiansen, U; Liljefors, T; Krogsgaard-Larsen, P. (2002) GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem, 2 (8): 817-32. [PMID:12171573]
Galanopoulou, AS. (2010) Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch., 460 (2): 505-23. [PMID:20352446]
Hanchar, HJ; Wallner, M; Olsen, RW. (2004) Alcohol effects on gamma-aminobutyric acid type A receptors: are extrasynaptic receptors the answer?. Life Sci., 76 (1): 1-8. [PMID:15501475]
Hemmings, HC; Akabas, MH; Goldstein, PA; Trudell, JR; Orser, BA; Harrison, NL. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol. Sci., 26 (10): 503-10. [PMID:16126282]
Herd, MB; Belelli, D; Lambert, JJ. (2007) Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol. Ther., 116 (1): 20-34. [PMID:17531325]
Hosie, AM; Wilkins, ME; Smart, TG. (2007) Neurosteroid binding sites on GABA(A) receptors. Pharmacol. Ther., 116 (1): 7-19. [PMID:17560657]
Jacob, TC; Moss, SJ; Jurd, R. (2008) GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci., 9 (5): 331-43. [PMID:18382465]
Johnston, GA. (2005) GABA(A) receptor channel pharmacology. Curr. Pharm. Des., 11 (15): 1867-85. [PMID:15974965]
Johnston, GA; Chebib, M; Hanrahan, JR; Mewett, KN. (2010) Neurochemicals for the investigation of GABA(C) receptors. Neurochem. Res., 35 (12): 1970-7. [PMID:20963487]
Korpi, ER; Debus, F; Linden, AM; Malécot, C; Leppä, E; Vekovischeva, O; Rabe, H; Böhme, I; Aller, MI; Wisden, W; et al.. (2007) Does ethanol act preferentially via selected brain GABAA receptor subtypes? the current evidence is ambiguous. Alcohol, 41 (3): 163-76. [PMID:17591542]
Korpi, ER; Gründer, G; Lüddens, H. (2002) Drug interactions at GABA(A) receptors. Prog. Neurobiol., 67 (2): 113-59. [PMID:12126658]
Krogsgaard-Larsen, P; Frølund, B; Liljefors, T. (2002) Specific GABA(A) agonists and partial agonists. Chem Rec, 2 (6): 419-30. [PMID:12469353]
Luscher, B; Fuchs, T; Kilpatrick, CL. (2011) GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron, 70 (3): 385-409. [PMID:21555068]
Mody, I; Pearce, RA. (2004) Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci., 27 (9): 569-75. [PMID:15331240]
Munro, G; Ahring, PK; Mirza, NR. (2009) Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol. Sci., 30 (9): 453-9. [PMID:19729210]
Möhler, H. (2006) GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J. Recept. Signal Transduct. Res., 26 (5-6): 731-40. [PMID:17118808]
Möhler, H. (2007) Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J. Neurochem., 102 (1): 1-12. [PMID:17394533]
Möhler, H; Fritschy, JM; Vogt, K; Crestani, F; Rudolph, U. (2005) Pathophysiology and pharmacology of GABA(A) receptors. Handb Exp Pharmacol, (169): 225-47. [PMID:16594261]
Ng, CK; Kim, HL; Gavande, N; Yamamoto, I; Kumar, RJ; Mewett, KN; Johnston, GA; Hanrahan, JR; Chebib, M. (2011) Medicinal chemistry of ρ GABAC receptors. Future Med Chem, 3 (2): 197-209. [PMID:21428815]
Nutt, DJ; Stahl, SM. (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J. Psychopharmacol. (Oxford), 24 (11): 1601-12. [PMID:19942638]
Olsen, RW; Chang, CS; Li, G; Hanchar, HJ; Wallner, M. (2004) Fishing for allosteric sites on GABA(A) receptors. Biochem. Pharmacol., 68 (8): 1675-84. [PMID:15451411]
Olsen, RW; Li, GD. (2011) GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth, 58 (2): 206-15. [PMID:21194017]
Olsen, RW; Sieghart, W. (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev., 60 (3): 243-60. [PMID:18790874]
Olsen, RW; Sieghart, W. (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology, 56 (1): 141-8. [PMID:18760291]
Rudolph, U; Möhler, H. (2004) Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol., 44: 475-98. [PMID:14744255]
Rudolph, U; Möhler, H. (2006) GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol, 6 (1): 18-23. [PMID:16376150]
Semyanov, A; Walker, MC; Kullmann, DM; Silver, RA. (2004) Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci., 27 (5): 262-9. [PMID:15111008]
Sieghart, W. (2006) Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol., 54: 231-63. [PMID:17175817]
Sigel, E; Lüscher, BP. (2011) A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr Top Med Chem, 11 (2): 241-6. [PMID:21189125]
Tan, KR; Rudolph, U; Lüscher, C. (2011) Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci., 34 (4): 188-97. [PMID:21353710]
Veleiro, AS; Burton, G. (2009) Structure-activity relationships of neuroactive steroids acting on the GABAA receptor. Curr. Med. Chem., 16 (4): 455-72. [PMID:19199916]
Vithlani, M; Terunuma, M; Moss, SJ. (2011) The dynamic modulation of GABA(A) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. Physiol. Rev., 91 (3): 1009-22. [PMID:21742794]
Wallner, M; Hanchar, HJ; Olsen, RW. (2006) Low dose acute alcohol effects on GABA A receptor subtypes. Pharmacol. Ther., 112 (2): 513-28. [PMID:16814864]
Whiting, PJ. (2003) The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel, 6 (5): 648-57. [PMID:14579514]
Zeller, A; Jurd, R; Lambert, S; Arras, M; Drexler, B; Grashoff, C; Antkowiak, B; Rudolph, U. (2008) Inhibitory ligand-gated ion channels as substrates for general anesthetic actions. Handb Exp Pharmacol, (182): 31-51. [PMID:18175085]
Zhang, D; Pan, ZH; Awobuluyi, M; Lipton, SA. (2001) Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol. Sci., 22 (3): 121-32. [PMID:11239575]
1. Atack, JR. (2008) GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. CNS Neurosci Ther, 14 (1): 25-35. [PMID:18482097]
2. Atack, JR. (2010) GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci, 2: 331-60. [PMID:21309116]
3. Barnard, EA; Skolnick, P; Olsen, RW; Mohler, H; Sieghart, W; Biggio, G; Braestrup, C; Bateson, AN; Langer, SZ. (1998) International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev., 50 (2): 291-313. [PMID:9647870]
4. Belelli, D; Harrison, NL; Maguire, J; Macdonald, RL; Walker, MC; Cope, DW. (2009) Extrasynaptic GABAA receptors: form, pharmacology, and function. J. Neurosci., 29 (41): 12757-63. [PMID:19828786]
5. Belelli, D; Lambert, JJ. (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci., 6 (7): 565-75. [PMID:15959466]
6. Bianchi, MT; Macdonald, RL. (2003) Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns. J. Neurosci., 23 (34): 10934-43. [PMID:14645489]
7. Bonin, RP; Orser, BA. (2008) GABA(A) receptor subtypes underlying general anesthesia. Pharmacol. Biochem. Behav., 90 (1): 105-12. [PMID:18201756]
8. Brown, N; Kerby, J; Bonnert, TP; Whiting, PJ; Wafford, KA. (2002) Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br. J. Pharmacol., 136 (7): 965-74. [PMID:12145096]
9. Capogna, M; Pearce, RA. (2011) GABA A,slow: causes and consequences. Trends Neurosci., 34 (2): 101-12. [PMID:21145601]
10. Chebib, M. (2004) GABAC receptor ion channels. Clin. Exp. Pharmacol. Physiol., 31 (11): 800-4. [PMID:15566397]
11. Chen, ZW; Olsen, RW. (2007) GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J. Neurochem., 100 (2): 279-94. [PMID:17083446]
12. Daniel, C; Ohman, M. (2009) RNA editing and its impact on GABAA receptor function. Biochem. Soc. Trans., 37 (Pt 6): 1399-403. [PMID:19909284]
13. Farrant, M; Nusser, Z. (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci., 6 (3): 215-29. [PMID:15738957]
14. Fisher, JL. (2002) Amiloride inhibition of gamma-aminobutyric acid(A) receptors depends upon the alpha subunit subtype. Mol. Pharmacol., 61 (6): 1322-8. [PMID:12021393]
15. Fisher, JL. (2009) The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology, 56 (1): 190-7. [PMID:18585399]
16. Frølund, B; Ebert, B; Kristiansen, U; Liljefors, T; Krogsgaard-Larsen, P. (2002) GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem, 2 (8): 817-32. [PMID:12171573]
17. Hemmings, HC; Akabas, MH; Goldstein, PA; Trudell, JR; Orser, BA; Harrison, NL. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol. Sci., 26 (10): 503-10. [PMID:16126282]
18. Herd, MB; Belelli, D; Lambert, JJ. (2007) Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol. Ther., 116 (1): 20-34. [PMID:17531325]
19. Hosie, AM; Wilkins, ME; Smart, TG. (2007) Neurosteroid binding sites on GABA(A) receptors. Pharmacol. Ther., 116 (1): 7-19. [PMID:17560657]
20. Jacob, TC; Moss, SJ; Jurd, R. (2008) GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci., 9 (5): 331-43. [PMID:18382465]
21. Johnston, GA. (2005) GABA(A) receptor channel pharmacology. Curr. Pharm. Des., 11 (15): 1867-85. [PMID:15974965]
22. Johnston, GA; Chebib, M; Hanrahan, JR; Mewett, KN. (2010) Neurochemicals for the investigation of GABA(C) receptors. Neurochem. Res., 35 (12): 1970-7. [PMID:20963487]
23. Khom, S; Strommer, B; Ramharter, J; Schwarz, T; Schwarzer, C; Erker, T; Ecker, GF; Mulzer, J; Hering, S. (2010) Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands - in vitro and in vivo characterization. Br. J. Pharmacol., 161 (1): 65-78. [PMID:20718740]
24. Korpi, ER; Debus, F; Linden, AM; Malécot, C; Leppä, E; Vekovischeva, O; Rabe, H; Böhme, I; Aller, MI; Wisden, W; et al.. (2007) Does ethanol act preferentially via selected brain GABAA receptor subtypes? the current evidence is ambiguous. Alcohol, 41 (3): 163-76. [PMID:17591542]
25. Korpi, ER; Gründer, G; Lüddens, H. (2002) Drug interactions at GABA(A) receptors. Prog. Neurobiol., 67 (2): 113-59. [PMID:12126658]
26. Krishek, BJ; Moss, SJ; Smart, TG. (1998) Interaction of H+ and Zn2+ on recombinant and native rat neuronal GABAA receptors. J. Physiol. (Lond.), 507 ( Pt 3): 639-52. [PMID:9508826]
27. Krogsgaard-Larsen, P; Frølund, B; Liljefors, T. (2002) Specific GABA(A) agonists and partial agonists. Chem Rec, 2 (6): 419-30. [PMID:12469353]
28. Li, GD; Chiara, DC; Cohen, JB; Olsen, RW. (2009) Neurosteroids allosterically modulate binding of the anesthetic etomidate to gamma-aminobutyric acid type A receptors. J. Biol. Chem., 284 (18): 11771-5. [PMID:19282280]
29. Li, GD; Chiara, DC; Sawyer, GW; Husain, SS; Olsen, RW; Cohen, JB. (2006) Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J. Neurosci., 26 (45): 11599-605. [PMID:17093081]
30. Luscher, B; Fuchs, T; Kilpatrick, CL. (2011) GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron, 70 (3): 385-409. [PMID:21555068]
31. Mody, I; Pearce, RA. (2004) Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci., 27 (9): 569-75. [PMID:15331240]
32. Möhler, H. (2007) Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J. Neurochem., 102 (1): 1-12. [PMID:17394533]
33. Ng, CK; Kim, HL; Gavande, N; Yamamoto, I; Kumar, RJ; Mewett, KN; Johnston, GA; Hanrahan, JR; Chebib, M. (2011) Medicinal chemistry of ρ GABAC receptors. Future Med Chem, 3 (2): 197-209. [PMID:21428815]
34. Olsen, RW; Li, GD. (2011) GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth, 58 (2): 206-15. [PMID:21194017]
35. Olsen, RW; Sieghart, W. (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev., 60 (3): 243-60. [PMID:18790874]
36. Olsen, RW; Sieghart, W. (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology, 56 (1): 141-8. [PMID:18760291]
37. Ramerstorfer, J; Furtmüller, R; Sarto-Jackson, I; Varagic, Z; Sieghart, W; Ernst, M. (2011) The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs. J. Neurosci., 31 (3): 870-7. [PMID:21248110]
38. Saxena, NC; Neelands, TR; MacDonald, RL. (1997) Contrasting actions of lanthanum on different recombinant gamma-aminobutyric acid receptor isoforms expressed in L929 fibroblasts. Mol. Pharmacol., 51 (2): 328-35. [PMID:9203639]
39. Semyanov, A; Walker, MC; Kullmann, DM; Silver, RA. (2004) Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci., 27 (5): 262-9. [PMID:15111008]
40. Sergeeva, OA; Kletke, O; Kragler, A; Poppek, A; Fleischer, W; Schubring, SR; Görg, B; Haas, HL; Zhu, XR; Lübbert, H; et al.. (2010) Fragrant dioxane derivatives identify beta1-subunit-containing GABAA receptors. J. Biol. Chem., 285 (31): 23985-93. [PMID:20511229]
41. Sieghart, W. (2006) Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol., 54: 231-63. [PMID:17175817]
42. Sigel, E; Lüscher, BP. (2011) A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr Top Med Chem, 11 (2): 241-6. [PMID:21189125]
43. Stórustovu, SI; Ebert, B. (2006) Pharmacological characterization of agonists at delta-containing GABAA receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2. J. Pharmacol. Exp. Ther., 316 (3): 1351-9. [PMID:16272218]
44. Thompson, SA; Bonnert, TP; Cagetti, E; Whiting, PJ; Wafford, KA. (2002) Overexpression of the GABA(A) receptor epsilon subunit results in insensitivity to anaesthetics. Neuropharmacology, 43 (4): 662-8. [PMID:12367611]
45. Thompson, SA; Smith, MZ; Wingrove, PB; Whiting, PJ; Wafford, KA. (1999) Mutation at the putative GABA(A) ion-channel gate reveals changes in allosteric modulation. Br. J. Pharmacol., 127 (6): 1349-58. [PMID:10455284]
46. Thompson, SA; Wheat, L; Brown, NA; Wingrove, PB; Pillai, GV; Whiting, PJ; Adkins, C; Woodward, CH; Smith, AJ; Simpson, PB; et al.. (2004) Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. Br. J. Pharmacol., 142 (1): 97-106. [PMID:15100159]
47. Veleiro, AS; Burton, G. (2009) Structure-activity relationships of neuroactive steroids acting on the GABAA receptor. Curr. Med. Chem., 16 (4): 455-72. [PMID:19199916]
48. Vithlani, M; Terunuma, M; Moss, SJ. (2011) The dynamic modulation of GABA(A) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. Physiol. Rev., 91 (3): 1009-22. [PMID:21742794]
49. Wafford, KA; van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ. (2009) Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus. Neuropharmacology, 56 (1): 182-9. [PMID:18762200]
50. Wallner, M; Hanchar, HJ; Olsen, RW. (2006) Low dose acute alcohol effects on GABA A receptor subtypes. Pharmacol. Ther., 112 (2): 513-28. [PMID:16814864]
51. Whiting, PJ. (2003) The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel, 6 (5): 648-57. [PMID:14579514]
52. You, H; Kozuska, JL; Paulsen, IM; Dunn, SM. (2010) Benzodiazepine modulation of the rat GABAA receptor α4β3γ2L subtype expressed in Xenopus oocytes. Neuropharmacology, 59 (6): 527-33. [PMID:20638393]
53. Zhang, D; Pan, ZH; Awobuluyi, M; Lipton, SA. (2001) Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol. Sci., 22 (3): 121-32. [PMID:11239575]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |


The potency and efficacy of many GABA agonists varies between receptor GABAA receptor isoforms [16,27]. For example, THIP (gaboxadol) is a partial agonist at receptors with the subunit composition α4β3γ2, but elicits currents in excess of those evoked by GABA at the α4β3δ receptor where GABA itself is a low efficacy agonist [6,8]. The antagonists bicuculline and gabazine differ in their ability to suppress spontaneous openings of the GABAA receptor, the former being more effective [45]. The presence of the γ subunit within the heterotrimeric complex reduces the potency and efficacy of agonists [43]. The GABAA receptor contains distinct allosteric sites that bind barbiturates and endogenous (e.g., 5α-pregnan-3α-ol-20-one) and synthetic (e.g., alphaxalone) neuroactive steroids in a diastereo- or enantio-selective manner [5,18-19,47]. Picrotoxinin and TBPS act at an allosteric site within the chloride channel pore to negatively regulate channel activity; negative allosteric regulation by γ-butyrolactone derivatives also involves the picrotoxinin site, whereas positive allosteric regulation by such compounds is proposed to occur at a distinct locus. Many intravenous (e.g., etomidate, propofol) and inhalational (e.g., halothane, isoflurane) anaesthetics and alcohols also exert a regulatory influence upon GABAA receptor activity [7,34]. Specific amino acid residues within GABAA receptor α- and β-subunits that influence allosteric regulation by anaesthetic and non-anaesthetic compounds have been identified [17,19]. Photoaffinity labelling of distinct amino acid residues within purified GABAA receptors by the etomidate derivative, [3H]azietomidate, has also been demonstrated [29] and this binding subject to positive allosteric regulation by anaesthetic steroids [28]. An array of natural products including flavonoid and terpenoid compounds exert varied actions at GABAA receptors (reviewed in detail in [21]).
In addition to the agents listed in the table, modulators of GABAA receptor activity that exhibit subunit dependent activity include: salicylidene salicylhydrazide [negative allosteric modulator selective for β1- versus β2-, or β3-subunit-containing receptors [46]]; fragrent dioxane derivatives [positive allosteric modulators selective for β1- versus β2-, or β3-subunit-containing receptors [40]]; loreclezole, etomidate, tracazolate, mefenamic acid, etifoxine, stiripentol, valerenic acid amide [positive allosteric modulators with selectivity for β2/β3- over β1-subunit-containing receptors [15,23,25]]; tracazolate [intrinsic efficacy, i.e., potentiation, or inhibition, is dependent upon the identity of the γ1-3-, δ-, or ε-subunit co-assembed with α1- and β1-subunits [44]]; amiloride [selective blockade of receptors containing an α6-subunit [14]]; furosemide [selective blockade of receptors containing an α6-subunit co-assembled with β2/β3-, but not β1-subunit [25]]; La3+ [potentiates responses mediated by α1β3γ2L receptors, weakly inhibits α6β3γ2L receptors, and strongly blocks α6β3δ and α4β3δ receptors [8,38]]; ethanol [selectively potentiates responses mediated by α4β3δ and α6β3δ receptors versus receptors in which β2 replaces β3, or γ replaces δ [50], but see also [24]]; DS1 and DS2 [selectively potentiate responses mediated by δ-subunit-containing receptors [49]]. It should be noted that the apparent selectivity of some positive allosteric modulators (e.g., neurosteroids such as 5α-pregnan-3α-ol-20-one for δ-subunit-containing receptors (e.g., α1β3δ) may be a consequence of the unusually low efficacy of GABA at this receptor isoform [4,6].